Logo 1 Logo 2

Clinical Trial Details

Trial ID: L6804
Source ID: NCT04184947
Associated Drug: Sglt2 Inhibitor
Title: Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes
Interventions: DRUG: SGLT2 inhibitor|DRUG: GLP-1 receptor agonist
Outcome Measures: Primary: 3 point major adverse cardiovascular events (4P-MACE), First occurrence of myocardial infarction, stroke, or death, 3-26 months after index date | Secondary: Hospitalization for cardiovascular causes, First hospitalization for any cardiovascular cause, 3-26 months after index date|Death, All-cause death, 3-26 months after index date|Myocardial infarction, Myocardial infarction, 3-26 months after index date|Heart failure, Hospitalization for heart failure, 3-26 months after index date|Stroke, Stroke or transient ischemic attack, 3-26 months after index date|Revascularization, Any arterial site revascularization (surgical or endovascular), 3-26 months after index date | Other: Occurrence of adverse events, Occurrence of: amputation, Fournier's gangrene, bone fracture, diabetic ketoacidosis, infections, pancreatitis, pancreatic cancer, acute kidney injury, 3-26 months after index date
Sponsor/Collaborators: Sponsor: University of Padova
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 10000
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2014-03-01
Completion Date: 2020-02-29
Results First Posted:
Last Update Posted: 2020-03-11
Locations: Division of Metabolic Diseases, University Hospital of Padova, Padova, 35128, Italy
URL: https://clinicaltrials.gov/show/NCT04184947